EJEntsar Hadi Jawad

Entsar Hadi Jawad

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Entsar Hadi Jawad has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Formulation and Characterization of Lipophilic Chemotherapy as Ethosomal Gel for Cervical Cancer

    by Maryam Alaayedi, Zahraa Mohammed Kadhim, Jamal Ali Ashoor, Ashti Mh Saeed, Jinan M Al-Mousawy, Hasanain Shakir Mahmood, Entsar H. Jawad, Mustafa H. Alhamadani

    Aim: methotrexate was formulated as Ethosomal gel for enhancing the therapeutic performance and stability to treat cervical cancer via targeting the drug locally through cervical mucosa to avoid the systemic adverse effect of the chemotherapy. Materials and Methods: The formulations were produced using phospholipid and cholesterol then evaluated for particle size, polydispersity index, zeta potential, pH and drug release. The optimized ethosome formula then converted to gel. The gel evaluated for organoleptic properties, pH, viscosity and permeability. Results: The results showed than F8 was the best ethosomal formula with 34nm in size and 92% entrapment efficiency. This formula converted into gel had 1% gelling agent that was optimized ethosomal gel formula and gave better release that ordinary methotrexate gel with same type and percent of gelling agent. Conclusions: The drug was successfully formulated as ethosomal gel for treating cervical cancer topically in order to avoid the systemic exposure for the chemotherapy and its consequence adverse effect.

  • Open Access

    A review on nanotechnology in drug delivery systems for cancer therapy

    by Alhasan Ali Jabbar, Sarah Mohammed Altamimi, Nawres Bahaa Mohammed, Istabraq Saeed Abaas, Entsar Hadi Jawad, Hany Al-Hussaniy, Zamri Chik, Hassan A. Almoustafa

    Background : Nanotechnology has introduced several clinically validated drug-delivery platforms that have improved pharmacokinetic profiles and reduced selected toxicities in specific cancer indications. Materials and methods : This review was conducted by searching search engines such as Google Scholar, PubMed, and ScienceDirect using several keywords, such as “nanomedicine,” “lipid-based carriers,” “polymeric nanoparticles,” “dendrimers,” and “precision medicine.” The articles on precision medicine related to targeted therapy and gene therapy, artificial intelligence, and related large language models were excluded, and publications with unreliable, unverifiable, or inaccessible data, including non-peer-reviewed sources, were also excluded. Results : Recent advancements have also enabled the integration of diagnostic and therapeutic functions within a single nanocarrier, paving the way for theranostic applications and real-time treatment monitoring. Despite these significant achievements, challenges such as large-scale manufacturing, stability, immunogenicity, and long-term safety remain substantial barriers to clinical translation. Conclusion : Continuous efforts to develop biocompatible, cost-effective, and personalized nanomedicine platforms are essential to transform nanotechnology-based drug delivery from an experimental concept into a reliable clinical reality that has demonstrated improved pharmacokinetics, tolerability, or clinical outcomes in selected indications, such as liposomal formulations including CPX-351 and pegylated liposomal doxorubicin.